Search

everythinglearnresearchcommunity

for

Search:↓

Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.

People with moderate hair loss from Alopecia Areata feel more impacted than those with no or almost complete hair loss, and are more likely to seek treatment.

Improving symptoms of male urinary problems may lower the risk of death.

Mothers with atopic dermatitis have higher risks of pregnancy complications and their children are more likely to develop certain health issues.

Diffuse hair loss significantly worsens quality of life for females, especially younger women and those with long-term hair loss.

AI can accurately measure hair loss severity in alopecia areata.

Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.

Men with hair loss experience lower quality of life, worsened by factors like age, severity, and treatment history.

Moderate facial angiofibroma significantly reduces quality of life compared to almost-clear cases, highlighting the benefits of treatment.

Young adults who had liver disease as children often experience significant health problems and frequently need transplants.

Alopecia areata affects women and young adults most, with low SDI regions seeing the highest increase, and new treatments like JAK inhibitors are being explored.

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.

Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.

The number of new cases of cutaneous B-cell lymphoma has leveled off since the early 2000s, and survival rates have improved since 1973.

Diagonal earlobe crease and lipoprotein(a) together help diagnose coronary heart disease.

The Brigham Eyelash Tool for Alopecia (BELA) is a reliable way to measure eyelash loss in alopecia areata patients.

Discoid Lupus Erythematosus often causes scarring hair loss, is influenced by genetics and environment, and requires early treatment to prevent worsening.

Standardized definitions and better methods are needed to accurately estimate long COVID-19 prevalence.

Premature graying of hair significantly harms psychological and social wellbeing.

The document concludes that scalp disorders can be treated with hair washing, specific shampoos, medications, and sometimes surgery or hair transplants, but hereditary baldness is untreatable.

Androgenetic alopecia affects men's emotions more than symptoms or daily function.

An AI device for skin cancer was successfully integrated into the NHS, improving diagnosis accuracy and service capacity.

Women with skin conditions who have body image concerns often experience mental health issues and a lower quality of life.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

Scoring systems help doctors assess and treat skin diseases effectively.

The updated SALT II tool offers a more precise way to measure scalp hair loss.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

The Hair660™ light therapy device effectively and safely improves hair density in people with androgenetic alopecia.